Parallel Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Parallel Advisors’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,294	Closed	-$11.2K	–	3687
2024 Q4	$11.2K	Hold	3,294	–	–	﹤0.01%	2377
2024 Q3	$9.39K	Hold	3,294	–	–	﹤0.01%	2415
2024 Q2	$7.41K	Hold	3,294	–	–	﹤0.01%	2415
2024 Q1	$7.28K	Hold	3,294	–	–	﹤0.01%	2426
2023 Q4	$7.74K	Hold	3,294	–	–	﹤0.01%	2380
2023 Q3	$6.13K	Hold	3,294	–	–	﹤0.01%	2432
2023 Q2	$8.63K	Hold	3,294	–	–	﹤0.01%	2233
2023 Q1	$5.37K	Hold	3,294	–	–	﹤0.01%	2387
2022 Q4	$4.38K	Sell	3,294 -3,906	-54%	-$5.51K	﹤0.01%	2389
2022 Q3	$11K	Hold	7,200	–	–	﹤0.01%	1977
2022 Q2	$11K	Hold	7,200	–	–	﹤0.01%	1951
2022 Q1	$19K	Hold	7,200	–	–	﹤0.01%	1761
2021 Q4	$21K	Hold	7,200	–	–	﹤0.01%	1766
2021 Q3	$18K	Hold	7,200	–	–	﹤0.01%	1808
2021 Q2	$29K	Hold	7,200	–	–	﹤0.01%	1499
2021 Q1	$32K	Hold	7,200	–	–	﹤0.01%	1384
2020 Q4	$35K	Hold	7,200	–	–	﹤0.01%	1246
2020 Q3	$43K	Hold	7,200	–	–	﹤0.01%	1123
2020 Q2	$19K	Buy	+7,200	New	+$25.1K	﹤0.01%	1444

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Parallel Advisors's XERS Position: Q1 2025 in Review

Parallel Advisors sold out of Xeris Biopharma Holdings (XERS) in Q1 2025, closing a stake of 3,294 shares — an estimated $11.2K sold.

Parallel Advisors first reported a position in XERS in Q2 2020 and held it in 19 quarters. The position peaked at $43K in Q3 2020. 199 funds tracked by Wall St. Rank hold XERS as of Q1 2025.

Parallel Advisors reported no remaining Xeris Biopharma Holdings position as of Q1 2025 after selling out during the quarter.
Parallel Advisors sold 3,294 Xeris Biopharma Holdings shares in Q1 2025, an estimated $11.2K.
Parallel Advisors first reported a position in Xeris Biopharma Holdings in Q2 2020 and held it in 19 quarters.
Parallel Advisors's Xeris Biopharma Holdings position peaked at $43K in Q3 2020.
199 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2025.

Based on Parallel Advisors's 13F filing for Q1 2025, filed 8 Apr 2025.